AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues
First Full Year Growth Since 2011
With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat.
You may also be interested in...
Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.
The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off?
The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.